ArticleAging2021
Increased plasma brain-derived neurotrophic factor (BDNF) as a potential biomarker for and compensatory mechanism in mild cognitive impairment: a case-control study.
Article in Aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07180147 (Arlington Longitudinal Optimal Healthy Aging Study), which is not on this map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Arlington Longitudinal Optimal Healthy Aging Study (ALOHA)
Who cites it
33 citing papers in PubMed, 42 citations in OpenAlex.
- Deregulation of Synaptic Plasticity-Related MicroRNAs After Repetitive Transcranial Magnetic Stimulation in Alzheimer's Disease.Molecular neurobiology · 2026Trial
- Cognitive and Pyroptotic Outcomes of Neonatal Ketamine and Dexmedetomidine: Potential Neuroprotection via Caspase-1 Modulation.Developmental neurobiology · 2026Article
- Quercetin nanoparticles exhibit a potential therapeutic effect against the neurochemical changes and motor deficits in a rat model of Parkinson's disease.Scientific reports · 2026Article
- Quetiapine ameliorates sensorimotor gating, recognition memory, and neuroendocrine plasticity in chronic stress-induced female rats.Metabolic brain disease · 2026Article
- Disruption of BDNF signalling in neuropathologies.Biochemical Society transactions · 2026Review
- Plasma BDNF levels in children with ADHD before and after methylphenidate treatment.Scandinavian journal of child and adolescent psychiatry and psychology · 2026Article
- Measurement Error and Methodologic Issues in Analyses of the Proportion of Variance Explained in Cognition.Neuropsychology review · 2025Review
- Article
- Brain-derived neurotrophic factor and its relationship to known biomarkers of Alzheimer's disease.Journal of Alzheimer's disease : JAD · 2025Article
- Unveiling blood biomarkers for neuronal hyperplasticity: Insights from AD molecular subtyping, a comprehensive review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Evaluation of serum brain-derived neurotrophic factor, IL-6, IL-10, and TNF-a cognitive function, and sleep quality in elderly patients with major depressive disorder and somatic symptoms.Journal of medical biochemistry · 2025Article
- Deregulation of Neuroinflammatory and Neurotrophic Factors as Biological Events Triggered by D-Galactose Chronic Administration in Wistar Rats.Neuromolecular medicine · 2025Article
- Article
- From Synaptic Plasticity to Neurodegeneration: BDNF as a Transformative Target in Medicine.International journal of molecular sciences · 2025Review
- Huanglian Wendan Decoction Improves Insomnia in Rats by Regulating BDNF/TrkB Signaling Pathway Through Gut Microbiota-Mediated SCFAs and Affecting Microglia Polarization.Molecular neurobiology · 2025Article
- Correlation between cortical morphology and synaptic-associated proteins levels in poststroke aphasia: a pilot study.Frontiers in psychology · 2025Article
- Comprehensive metabolomics profiling reveals novel biomarkers and pathways for early detection of Alzheimer's disease.Brain communications · 2025Article
- Association of plasma BDNF and MMP-9 levels with mild cognitive impairment: a matched case-control study.Scientific reports · 2024Article
- Neuroprotective effects of punicalagin and/or micronized zeolite clinoptilolite on manganese-induced Parkinson's disease in a rat model: Involvement of multiple pathways.CNS neuroscience & therapeutics · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious meta-analyses examining the continuum of Alzheimer's disease (AD) concluded significantly decreased peripheral brain-derived neurotrophic factor (BDNF) in AD. However, across different meta-analyses, there remain inconsistent findings on peripheral BDNF levels in individuals with mild cognitive impairment (MCI). This issue has been attributed to the highly heterogenous clinical and laboratory factors. Thus, BDNF's level, discriminative accuracy for identifying all-cause MCI and its subtypes, and its associations with other biomarkers and neurocognitive domains, remain largely unknown.
methodsTo address this heterogeneity, we compared a healthy control cohort (n=56, 45 female) to an MCI cohort (n=40, 28 female), to determine whether plasma BDNF, hs-CRP, and DHEA-S can differentiate healthy from MCI individuals, including two MCI subtypes (amnestic [aMCI] and non-amnestic [non-aMCI]). The associations between BDNF with other biomarkers and neurocognitive tests were examined. Adults with cerebral palsy were included as sensitivity analyses.
resultsCompared to healthy controls, BDNF was significantly higher in all-cause MCI, aMCI, and non-aMCI. Furthermore, BDNF had good (AUC=0.84, 95% CI=0.74 to 0.95, p<0.001) and excellent discriminative accuracies (AUC=0.92, 95% CI=0.84 to 1.00, p<0.001) for all-cause MCI and non-amnestic MCI, respectively. BDNF was significantly and positively associated with plasma hs-CRP (β=0.26, 95% CI=0.02 to 0.50, p=0.038), despite attenuated association upon controlling for BMI (β=0.15, 95% CI=-0.08 to 0.38, p=0.186). Multiple inverse associations between BDNF and detailed neurocognitive tests were also detected.
conclusionsThese findings suggest BDNF is increased as a compensatory mechanism in preclinical dementia, supporting the neurotrophic and partially the inflammatory hypotheses of cognitive impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.